| Piedmont Lithium (NASDAQ: PLL) Announces Positive Results from Pre-Feasibility Study |
| |
|
Piedmont Lithium (NASDAQ: PLL) positive results from pre-feasibility study (“PFS”) level metallurgical test work conducted on composite samples of ore from the Piedmont Lithium Project (“Project”) performed at SGS testing laboratories in Lakefield, Ontario.
Why It Matters: Testwork confirms the company’s ability to produce high-grade, low impurity spodumene concentrate, and process simulations based on testwork results support a design basis of 85% lithium recovery. Mineralogy shows spodumene as the only lithium bearing mineral in concentrate, and optimization to further improve recoveries will be undertaken during the Definitive Feasibility Study. Updated flow sheet will be reflected in a Scoping Study update expected in the next 30 days.
Key Quote: “We are very pleased with the results of this PFS-level testwork program, which confirms the outstanding mineralogy and metallurgy of the Piedmont Lithium Project. We look forward to reflecting these strong results in our forthcoming Scoping Study update, which will also incorporate the substantially larger mineral resource announced in June as well as several other constructive refinements.” — Keith Phillips, President & CEO
Background:Piedmont Lithium is an emerging lithium company focused on the development of its 100%-owned Piedmont Lithium Project in North Carolina, with the goal of becoming a strategic domestic supplier of lithium to the increasing electric vehicle and battery storage markets in the U.S. The Piedmont Lithium Project is located in one of the premier regions in the world for lithium exploration given its favorable geology and ideal location with easy access to infrastructure, power, R&D centers for lithium and battery storage and major high-tech population centers.
Disclosure
Piedmont Lithium (NASDAQ: PLL) is a client of RedChip Companies, Inc. PLL agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services
|
|
| |
|
| Nemaura Medical (NASDAQ: NMRD) Submits FNemaura Medical (NASDAQ: NMRD) Appoints Chris Avery VP of Global Business Operations to Support Launch of SugarBEAT® |
| |
|
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, announced the appointment of Chris Avery as Vice President of Global Business Operations to help oversee the commercial launch of SugarBEAT(R), including expansion of the Company's global licensee and distributor relationships.
Why It Matters: Avery brings over 30 years of senior experience in the healthcare industry with a focus on launching products, establishing distribution channels, and developing international relationships. Previously, Mr. Avery co-founded DiagnoSys Medical, a UK medical device distribution company. In this role, Avery recruited, trained, and launched a field-based sales team and was responsible for negotiating the sale of the business to Home Diagnostics. Subsequently, Avery served as European Director and UK Managing Director at Home Diagnostic Inc. During his tenure at Home Diagnostics, Avery launched the company's glucose monitoring portfolio, Orbus Stents and Animas insulin pumps, into the UK and helped build the European distribution network. Following Home Diagnostics, Avery served as European Director and UK Managing Director at Nipro Diagnostics, a company dedicated to helping people with diabetes manage their disease by providing blood glucose monitoring systems and other diabetes products. While at Nipro, he re-focused the organization, delivering a new strategic direction and leadership that increased market penetration. Additionally, Avery established and managed the sales operations for the organization within various regions and oversaw distributors within the EU and Africa.
Key Quote: “We are pleased to welcome Chris to the senior management team at Nemaura, as he brings extensive knowledge of SugarBEAT® and a proven track record within the diabetes space. In addition, to overseeing our collaboration with DBE in Europe, we look forward to Chris' increased involvement in overseeing our global rollout through licensees and global distributors given his sector expertise and extensive relationships. Moreover, we look forward to Chris' involvement in the launch of our related digital services.” — Dr. Faz Chowdhury, CEO
Disclosure
Nemaura Medical (NASDAQ: NMRD) is a client of RedChip Companies. NMRD agreed to pay RedChip a monthly cash fee for investor awareness services.
|
|
| |
|
| GSRX Industries (OTCQB: GSRX) Expected to Report Record Revenue of $3.5M for Q2 |
| |
|
GSRX Industries (OTCQB: GSRX) announced that it expects to report $3.5 million in revenue for the second quarter of 2019, the high end of previously issued guidance and a new quarterly record
Why It Matters: GSRX has generated tremendous growth in its first full year of operations and with its expectations for the second quarter, it is now operating at a $14 million annual revenue run rate. With a solid track record of five consecutive quarters of growth, GSRX added a COO role to its executive team last week, naming Andrew Alvis to the new position. Alvis is a seasoned executive and leader, most recently hailing from Atilla Management, where he served as CFO of the multi-dimensional healthcare provider.
Key Quote: "We continue to see strong growth across the board in GSRX's operations.” — Les Ball, CEO
Background: GSRX is in the business of acquiring, developing, and operating retail cannabis dispensaries and non-THC CBD retail stores. GSRX also is in the process of expanding its business to include distribution, extraction and light manufacturing, and delivery of cannabis and cannabinoid products. Currently, GSRX operates five cannabis dispensaries in Puerto Rico under the name Green Spirit RX, one dispensary in California under the name The Green Room, and has five additional pre-qualified locations in Puerto Rico, all of which are in various phases of development and construction. GSRX also owns and operates the e-commerce site GetPureAndNatural.com, which offers a broad range of premium hemp extract products.
Disclosure
GSRX Industries (OTCQB: GSRX) is a client of RedChip Companies. RedChip Companies, Inc. received 1,000,000 registered shares of GSRX for consulting services. Be advised RedChip intends to sell some or all of its shares at any time, including when you are buying.
|
|
| |
|
| Exclusive Interview with Digital Ally (NASDAQ: DGLY) CEO Stanton Ross |
| |
|
RedChip Companies President and CEO Dave Gentry recently spoke with Stanton Ross, CEO of Digital Ally (NASDAQ: DGLY).
DGLY, headquartered in Lenexa, Kansas, specializes in the design and manufacturing of the highest quality video recording equipment and video analytic software. Digital Ally pushes the boundaries of technology in industries such as law enforcement, emergency management, commercial fleets, and consumer use.
The Company’s complete product solutions include in-car and body cameras, cloud and local management software, and automatic recording technology. These products work seamlessly together and are simple to install and operate. DGLY products are sold by domestic direct sales representatives and international distributors worldwide.
DGLY was added to the FTSE Russell Microcap Index in June.
Watch our exclusive interview to learn more about DGLY’s innovative products and growth potential.
Disclosure
Digital Ally, Inc. (NASDAQ: DGLY) is a client of RedChip Companies, Inc. DGLY agreed to pay RedChip Companies, Inc., a monthly cash fee for four (4) months of RedChip investor awareness services.
|
|
| |
|
| SinglePoint’s (OTCQB: SING) Direct Solar Expands into Commercial Market |
| |
|
SinglePoint (OTCQB: SING) subsidiary Direct Solar signed a funding agreement to supply small to medium commercial outfits with solar financing. This agreement is the first of its kind to make readily available to finance commercial building solar installations. Direct Solar now has the capability to work with these businesses to supply the contractor for installation and finance the transaction all in one seamless package.
Why It Matters: Until now, solar has had many options to finance large scale projects and residential solar projects. There has not been an easy way to obtain funding if you have a small to medium commercial operation. For these owners and managers this brings the opportunity to reduce electrical costs through solar and other renewable energy solutions Direct Solar will offer to commercial customers.
Key Quote: “We are beyond excited for the opportunity. We have already hired two new commercial side managers to lead the teams in their sales efforts. We have a pipeline of interested businesses that we now can finance. We have yet to find a solution like ours that we have now signed off on and we believe it will add a significant amount of opportunities and deals to our business. Opening the commercial side of our operations increases the number of potential contracts for us to close in the space. It is a completely untapped market in my opinion with a high chance for major success.” — Pablo Diaz, CEO of Direct Solar
Disclosure
SinglePoint, Inc. (OTCQB: SING) is a client of RedChip Companies, Inc. SING agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services
|
|
| |
|
| Catasys (NASDAQ: CATS) Appoints Industry Veteran Rob Rebak to Board of Directors |
| |
|
Catasys (NASDAQ: CATS), a leading AI and technology-enabled healthcare company, announced the appointment of Mr. Robert L. Rebak to its Board of Directors, replacing Mr. Richard J. Berman. The number of Board members remains at seven.
Mr. Terren Peizer, Chairman and CEO of Catasys, stated, “We are very pleased to welcome Rob to Catasys’ Board of Directors. Rob brings 30 years of experience in the healthcare industry, 20 of which have been spent leading several high-growth digital and tech-enabled health companies. Rob’s extensive industry relationships and prominence within the industry, as well as his cumulative expertise as a proven operator and strategist at companies in the behavioral healthcare space, will serve us well as we look to accelerate our growth trajectory. We wish Richard well and thank him for his significant contributions to Catasys.”
Key Quote: “Envision Solar has provided EV ARC products in more than 90 of the approximately 19,000 municipalities throughout the U.S. The successful delivery of this sizeable order to the largest city in the country clearly demonstrates our ability to scale up as we continue to grow.” — Desmond Wheatley, president and CEO of Envision Solar
The Backstory: : Catasys (NASDAQ: CATS) harnesses proprietary big data predictive analytics, artificial intelligence and telehealth, combined with human interaction, to deliver improved member health and validated outcomes and savings to health plans. Our mission is to help improve the health and save the lives of as many people as possible.
Catasys' (NASDAQ: CATS) integrated, technology-enabled OnTrak solution—contracted with a growing number of national and regional health plans—is designed to treat members with behavioral conditions that cause or exacerbate co-existing medical conditions such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure, which result in high medical costs.
Disclosure
Catasys (NASDAQ: CATS) is a client of RedChip Companies, Inc. CATS agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services.
|
|
| |
|
| Telemynd Provides Update Following Spinoff Transaction from Emmaus Life Sciences, Formerly MYnd Analytics |
| |
|
Telemynd, a predictive analytics company aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, provided a business update following its spinoff from Emmaus Life Sciences (“Emmaus”) (NASDAQ: EMMA), formerly MYnd Analytics
In connection with the merger between MYnd Analytics and Emmaus Life Sciences, MYnd Analytics contributed its business, assets and liabilities to Telemynd, which was spun off by means of a pro rata dividend of one share of Telemynd’s common stock for each share of MYnd common stock held at the end of trading on July 16, 2019. The new shares are expected to begin trading on a standalone basis, at which time further updates will be provided. In the meantime, additional information is available on the Company’s website and in the Company’s filings with the Securities and Exchange Commission.
The Backstory: Telemynd ("Telemynd") will now have two wholly owned subsidiaries: (i) Arcadian Telepsychiatry Services LLC, which is a technology-enabled telepsychiatry and teletherapy company that provides enhanced access to behavioral health services, improves patient outcomes and helps lower the costs associated with behavioral health issues; and (ii) MYnd Analytics, a provider of analytical predicative diagnostic tests for mental health professionals. The MYnd Psychiatric EEG Evaluation Registry (PEER) is a predictive analytics decision support tool that helps physicians reduce trial and error treatment for behavioral health conditions. PEER provides the physician a personalized care plan with recommended treatment options based on a patient’s unique brain markers, reducing treatment time and treatment costs. Telemynd will be offering Arcadian's suite of complementary telemedicine services that can be combined with MYnd's PEER, including telepsychiatry, teletherapy, digital patient screening, curbside consultation, on-demand services, and scheduled encounters for all age groups. Telemynd’s customers include major health plans, health systems, and community-based organizations.
Disclosure
MYnd Analytics, Inc. (NASDAQ: MYND) is a client of RedChip Companies, Inc. MYND agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services.
|
|
| |
|
| ChineseInvestors.com (OTCQB: CIIX) to Hold Webinar Wednesday |
| |
|
Warren Wang, CEO of ChineseInvestors.com (OTCQB: CIIX), a fast-growing company targeting Chinese consumers and investors in North America by providing financial news and commentary to Chinese Americans, and one of the first Chinese American public companies focused on selling CBD products on ChineseCBDoil.com, will host a webinar Wednesday, July 24, 2019 at 2 pm Eastern/11 am Pacific.
To register for the free webinar, please visit this webpage: redchip.com/corporate/webinar_register/44.
The webinar will be viewable on our home page, redchip.com. An archived version of the webinar will be available at redchip.com/events/44/ChineseInvestors-Webinar.
About ChineseInvestors.com (OTCQB: CIIX)
— Market cap: $18 million
— ChineseInvestors.com, founded in 1999, offers a proprietary financial news media and content platform providing information to the Chinese-speaking community in China, the United States and Canada, and the world
— CIIX is one of the first Chinese American public companies focused on selling CBD products on ChineseCBDoil.com, one of the world’s first online stores in the Chinese language offering industrial hemp-derived CBD products
— In 2017, the Company established a subsidiary in China, CBD Biotech, which focuses on the manufacture of CBD skin-care products for the Chinese population in Southeast Asia
— CIIX generated record revenue of $1.4M in 3QFY19, an 81% increase YoY, and CBD sales increased 579% YoY in the same quarter. Management expects to generate $11M-$12M in FY2020
View Investor Deck: slideshare.net/RedChip/ciix-investor-presentation-fall2018
More information: chineseinvestors.com, ciixinfo.com
Disclosure
ChineseInvestors.com, Inc. (OTCQB: CIIX) is a client of RedChip Companies. CIIX pays RedChip a monthly cash fee for twelve (12) months of investor awareness services.
|
|
| |
|
| Marker Therapeutics (NASDAQ: MRKR) Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR |
| |
|
Results show potential of MultiTAA therapy in combination with chemotherapy as a first-line treatment for patients with pancreatic cancer; potential second-line treatment for chemo-refractory patients
T cell infiltration and expansion observed, supporting MultiTAA's potential as a durable treatment in this patient population
Key Quote: "Pancreatic cancer continues to be one of the most challenging solid tumor malignancies to treat and survival rates have not seen a meaningful improvement in more than 40 years." — Brandon G. Smaglo, M.D., FACP, lead investigator and Assistant Professor of Oncology at Baylor College of Medicine
The Backstory: Marker Therapeutics is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
Disclosure
Marker Therapeutics Inc. (MRKR) is a client of RedChip Companies, Inc. MRKR agreed to pay RedChip Companies, Inc., a monthly cash fee for (4) months of RedChip investor awareness services.
|
|
| |
|
| eMARINE Global (OTC: EMRN) Awarded $500,000 Bridge Simulator Contract |
| |
|
eMARINE Global (OTC: EMRN), a leading provider of information and communications technology (ICT) for the maritime industry, signed a contract with Ulsan IT Industry Promotion Agency (UIPA) to develop a full mission ship bridge simulator for the National Autonomous Ships’ Test Bed in Ulsan, Korea. The contract is valued at an estimated 650 million won (US$0.5 million).
Why It Matters: The simulator is utilized to test the autonomous ships prior to sea-trial, to simulate their operation and traffic control in a virtual environment, and to acquire data from marine equipment for further testing and development. The test bed, in connection with the shore-based traffic control center, is being established to test, trial, evaluate, and develop autonomous ships. Ulsan was chosen as the national center for autonomous ship testing in 2018. The Korean government has committed to invest 130 billion won (US$110 million) in the project over the next three years, with a goal of starting operations in 2023. UIPA serves as project manager for the test bed construction.
Key Quote: “This simulator contract represents the cornerstone of the entire autonomous ship test bed project, a strategically significant project for Korea. eMARINE again proved itself and further demonstrated its leadership position in the rapidly evolving autonomous ship technology market.” — Ung Gyu Kim, Chairman and CEO
Background: Founded in 2001 and based in South Korea, eMARINE Global is working with a growing base of marquee customers to achieve maritime ICT convergence through fully integrated products and services, offering state-of-the-art e-navigation, marine Internet of Things (IoT), and marine big data solutions, primarily in Korea with near-term expansion into the U.S. and Chinese markets.
Disclosure
eMARINE Global (OTC: EMRN) is a client of RedChip Companies. RedChip Companies, Inc. owns 613,000 shares of EMRN common stock.
|
|
| |
|
| |
| Quote of the Week |
| |
"For me, the fun is to build, not to manage. I look for what's available, what is possible to do. That's the overriding consideration. There are a lot of things I would have liked to do, but didn't have the means."
- Dr. Phil Frost, Chairman OPKO Health |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
If you received this email by mistake you can unsubscribe from all emails.
|
|
|
|
|
| | |
